10-Q: Cryomass Technologies Reports Q2 2024 Results, Revenue Growth Offset by Net Losses

Cryomass Technologies saw revenue growth in Q2 2024, but continues to experience net losses and going concern uncertainty.

Summary

• Cryomass Technologies reported revenue of $13,889 for the three months ended June 30, 2024, and $19,189 for the six months ended June 30, 2024, compared to no revenue in the same periods of 2023.
• The company experienced a net loss of $1,619,727 for the three months ended June 30, 2024, and a net loss of $4,174,196 for the six months ended June 30, 2024.
• Operating expenses decreased significantly, primarily due to reduced personnel costs, general and administrative expenses, and the absence of impairment charges that were present in 2023.
• The company's cash balance was $497,900 as of June 30, 2024, and they have a working capital deficit of $5,996,694.
• Cryomass has a contingent royalty liability of $2,590,000 related to a net revenue sharing agreement.
• The company has issued shares and warrants to raise capital and convert debt.
• There is substantial doubt about the company's ability to continue as a going concern, dependent on future revenue, and additional financing.

Sentiment

Score: 3

Explanation: The document shows some positive signs with revenue generation and reduced operating expenses, but the significant net losses, working capital deficit, and going concern uncertainty create a negative sentiment. The company's reliance on future financing and the identified internal control weaknesses are also concerning.

Positives

• Cryomass Technologies has started generating revenue, with $13,889 in the three months ended June 30, 2024, and $19,189 in the six months ended June 30, 2024.
• The company has significantly reduced its operating expenses, decreasing by 82% for the three months and 72% for the six months ended June 30, 2024.
• The net loss has decreased substantially compared to the same periods in 2023.
• The company has successfully raised capital through the issuance of common stock and warrants.
• The company has converted debt into equity, reducing its liabilities.
• The company has installed its first commercial unit, the CryoSift Separator, at a licensee's location.

Negatives

• Cryomass Technologies continues to experience net losses, with a loss of $1,619,727 for the three months and $4,174,196 for the six months ended June 30, 2024.
• The company has a significant working capital deficit of $5,996,694.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is dependent on future revenue, and additional financing to fund its operations.
• The company has a contingent royalty liability of $2,590,000.
• The company's disclosure controls and procedures were not effective as of June 30, 2024.
• The company has identified significant deficiencies in its internal control over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain, depending on future revenue and additional financing.
• The company has a significant working capital deficit and may not have sufficient funds to cover its operating costs and capital expenditures.
• The company's internal controls over financial reporting are not effective, which could lead to material misstatements in financial statements.
• The company is subject to risks related to the cannabis and cannabinoid industries, including regulatory changes and competition.
• The company's technology may not be adopted by the industry as anticipated.
• The company's reliance on a limited number of customers and partners could impact its revenue stream.
• The company's intellectual property may not be adequately protected.

Future Outlook

The company expects to finance future cash needs from the results of operations and additional financing until the company can achieve profitability and positive cash flows from operating activities. However, there is no assurance that the company will receive sufficient cash flow from operations or otherwise that they will be able to attract the necessary financing.

Management Comments

• The company believes that its available cash balance as of the date of this filing will not be sufficient to fund its anticipated level of operations for at least the next twelve months.
• The company believes that, at the present time, its ability to continue operations depends on cash expected to be available from lease payments and royalty payments in connection with future revenue generation, as well as possible debt, equity or other investment sources, to fund its anticipated level of operations for at least the next twelve months.

Industry Context

The company operates in the cannabis and hemp industry, which is experiencing growth due to increasing acceptance of medicinal cannabis products and anticipated legislative changes. The company's technology aims to improve post-harvest methods and reduce costs for cultivators and processors.

Comparison to Industry Standards

• Cryomass is a small company in the cannabis technology sector, and its financial results are not directly comparable to larger, established companies in the industry.
• Companies like Canopy Growth, Tilray, and Aurora Cannabis are much larger and have significantly higher revenues, but also face challenges in achieving profitability.
• Cryomass's focus on trichome separation technology is a niche area, and there are few direct competitors with similar technology.
• The company's revenue is still very low compared to industry standards, but it is a positive sign that they are starting to generate revenue.
• The company's high operating expenses and net losses are not uncommon for early-stage companies in the cannabis industry, but they need to improve their financial performance to become sustainable.
• The company's going concern uncertainty is a significant concern, as many cannabis companies have struggled to achieve profitability and have faced financial difficulties.

Related Party Transactions

• The company entered into a loan agreement with CRYM Co-Invest LP, of which Alexander Massa, a 23.1% beneficial owner of the Company, has investment control.
• The company received $100,000, $50,000, and $25,000 from Simon Langelier, Health Diplomats Pte Ltd, and Mario Gobbo, respectively, who are directors of the company.
• The company received $80,000 related to a territory license fee from a related party.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and financial instability.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers may be affected by the company's ability to deliver products and services.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to continue to evaluate and strengthen its internal control over financial reporting.
• The company plans to develop or improve procedures to address the current significant deficiencies.
• The company will continue to seek additional financing to fund its operations.
• The company will work to achieve profitability and positive cash flows from operating activities.

Key Dates

Keywords

Cryomass, cannabis, hemp, trichome separation, cryogenic processing, CryoSift Separator, revenue, net loss, operating expenses, going concern, capital raise, intellectual property, financial reporting, internal controls